You are here » About Galderma » Company History

Company History

Dermatology company Galderma’s detailed timeline:

2016

Plant extension in Canada. 
Qilib is launched in the U.S. 
Expansion of Distribution agreement for Dysport to key areas in Asia.

2015

Galderma enters neutraceutical market with acquisition of certain Innéov assets. 
Opening of branch office/MEA regional headquarters in Dubai.
Launch of Soolantra cream 1% (rosacea) in the U.S. and Europe. 
Launch of Epiduo Forte Gel, 0.3%/2.5% in the U.S.

2014

Foundation of Nestlé Skin Health. Galderma is now fully-owned by Nestlé.
Galderma commercializes Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the U.S. and Canada.

2013

Acquisition of Swiss company Spirig Pharma AG, manufacturer of Daylong & Excipial.
FDA approval of Mirvaso for the treatment of erythema associated with rosacea.

2012

Galderma defines its new 3-business strategy and a new ambition statement.
Opening of a new affiliate in China.
Cetaphil Dermacontrol is launched in 6 countries.

2011

Acquisition of Q-Med, a Swedish company specialized in aesthetic & corrective solutions.
Emervel (dermal filler range) launch in Europe and Latin America.
Plant extensions in France and Canada.

2010

Galderma hits the 1 billion € mark in sales.
Launch of Cetaphil Restoraderm.
Differin Lotion 0.1% (acne) launch in the U.S.
Launch of Restylane Skincare series with NASHA™

2009

Launch of Vectical (psoriasis), Azzalure (glabellar lines) and Restylane Injector, an innovative type of injection device. 
Galderma purchases global rights, assets, and liabilities related to Metvix and Aktilite.
Restylane obtains registration approval in China and becomes the first injectable non-animal hyaluronic acid product on the Chinese market.

2008

Launch of Epiduo (acne).
Acquisition of CollaGenex Pharmaceuticals
and its product Oracea (rosacea).
Launch of Differin 0.1% Gel in Japan.

2007

Licensing agreements for Pliaglis (topical anesthetic) and a botulinum toxin Type A.
Launch of Differin 0.3%.

2006

Clobex Spray launch in the U.S.
Opening of the new R&D center in Sophia Antipolis, France.

2005

Metrogel 1% (rosacea) launch in the U.S.
Galderma becomes number One in D class (Dermatology)
(source: IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries).

2004

Inauguration of the new research and preclinical development building in Sophia Antipolis, France.
Opening of a new production site in Hortolandia, Brazil.
Clobex Shampoo launch in the U.S. and acquisition of Tri-Luma.

2003

Launch of Metvix in Germany and the UK and Clobex Lotion (psoriasis) in the U.S.
Restylane is approved in the U.S.

2002

Licensing agreements for Tri-Luma (pigmentary disorders) and Pekiron (Loceryl Cream) in Japan.
First FDA approvals for pharmaceutical production in Montreal.

2001

Licensing agreement for Metvix (skin cancer).

2000

The Montreal production unit comes on stream.
Launch of Silkis (psoriasis) and acquisition of Capex Shampoo (seborrheic dermatitis).

1999

Acquisition of Loceryl (fungal nail infections), developed by F. Hoffmann-La Roche Ltd, together with the Scandinavian dermatology portfolio developed by Nycomed.

1998

Inauguration of a new R&D facility in Princeton, New Jersey, U.S.
Acquisition in Brazil of Darrow’s dermatology portfolio.

1997

Acquisition of Basotherm, a subsidiary of Boehringer.

1996

Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant.
Restylane is approved for sales in Europe, for filling out of wrinkles and lip augmentation.

1995

Launch of anti-acne treatment Differin, Galderma’s first home-grown dermatology product.
The NASHA patent is filed.

1994

Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.

1993

Acquisition of MetroGel / Rozex to include rosacea treatments in the product portfolio.
Launch of Daylong by Spirig Pharma.

1989

New affiliates open in Canada, Germany, Spain and the United Kingdom.

1988

Galderma takes over Alcon’s dermatology business.

1987

Q-Med is founded by Bengt Ågerup with a view to commercializing the research that he had carried out around hyaluronic acid.

1986

Galderma’s first operations open for business in France, followed by a second affiliate in Italy.

1981

Nestlé and L'Oréal form a joint venture - Galderma - to become the world’s leading dermatology player. 

1979

L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology.

1977

Nestlé acquires Alcon.

1972

Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas, U.S.
Launch of Excipial by Spirig Pharma. 

1961

Creation of the Owen dermatology company in Dallas, Texas, U.S.

1948

Creation of Spirig Pharma in Olten, Switzerland.



Discover more about Galderma, a dermatology company providing dermatology solutions and aesthetic and corrective products internationally.

Follow us Follow us on twitter Follow us on Linkedin

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world

Read

Video

We are committed

See all videos